Compound Shows Promise as Next-Generation Prostate Cancer Therapy

Contact: Sarah Avery Phone: 919-660-1306 Email:sarah.avery@duke.eduhttps://www.dukehealth.orgEMBARGOED FOR RELEASE until 11 a.m. (ET) Monday, Aug. 8, 2016DURHAM, N.C. -- In the search for new ways to attack recurrent prostate cancer, researchers at Duke Health report that a novel compound appears to have a unique way of blocking testosterone from fueling the tumors in mice.The potential foundation for a next-generation therapy, called tetraaryl cyclobutane, or CB, is being studied as an option for prostate tumors that have grown resistant to current anti-androgen drugs, notably enzalutamide.“Prostate cancer is the most prevalent form of cancer in men, and the principal driver of tumor growth is the androgen receptor,” saidJohn D. Norris, Ph.D., associate research professor in theDepartment of Pharmacology&Cancer Biology at Duke and senior author of a study published online Aug. 8 in the journal Nature Chemical Biology.“Suppression of androgen receptor function by anti-endocrine therapies is initially effective, but most tumors develop resistance, resulting in a more aggressive cancer,” Norris said. “Our research has been focused on finding a new approach to suppressing androgen receptor activity, because ev en in situations where tumors are resistant to current therapies, the androgen receptor remains a viable target.”Norris and colleagues focused on a group of CB compounds developed in collaboration with scientists at the Universi...
Source: DukeHealth.org: Duke Health Features - Category: Pediatrics Tags: Duke Medicine Source Type: news

Related Links:

Publication date: Available online 16 April 2019Source: Seminars in Cancer BiologyAuthor(s): Samanta Salvi, Massimiliano Bonafè, Sara BravacciniAbstractThe possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent.The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients. The recent availability of selective AR inhibitors (e.g. bicalutamide, enzalutamide, apalutamide) approved for the treatment of prostate cancer has opened up the possibility to use them in BC ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Publication date: Available online 18 April 2019Source: Journal of Sport and Health ScienceAuthor(s): Xin Luan, Xiangyang Tian, Haixin Zhang, Rui Huang, Na Li, Peijie Chen, Ru WangAbstractA growing understanding of the benefits of exercise over the past few decades has prompted researchers to take an interest in the possibilities of exercise therapy. Because each sport has its own set of characteristics and physiological complications that tend to appear during exercise training, the effects and underlying mechanisms of exercise remain unclear. Thus, the first step in probing exercise effects on different diseases is the s...
Source: Journal of Sport and Health Science - Category: Sports Medicine Source Type: research
AbstractPurposePrimary breast and prostate cancers can be cured, but metastatic disease cannot. Identifying cell factors that predict metastatic potential could guide both prognosis and treatment.MethodsWe used Cell-SELEX to screen an RNA aptamer library for differential binding to prostate cancer cell lines with high vs. low metastatic potential. Mass spectroscopy, immunoblot, and immunohistochemistry were used to identify and validate aptamer targets. Aptamer properties were tested in vitro, in xenograft models, and in clinical biopsies. Gene expression datasets were queried for target associations in cancer.ResultsWe id...
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Dermatology
Source: Dermatology - Category: Dermatology Source Type: research
Conclusion In this article, we proposed a novel method LPI-IBNRA for predicting lncRNA-protein interactions, based on the known lncRNA-protein interactions, lncRNA expression similarity and protein-protein interactions. We integrated the known interactions and similarity as the initial resource scores for a two-round resource allocation of a bipartite network recommendation. Furthermore, we optimized the weight matrix by eliminating second-order correlations appropriately, to obtain the final result of lncRNA-protein interaction prediction. We finally acquired gratifying and reliable prediction performance in LOOCV, 10-fo...
Source: Frontiers in Genetics - Category: Genetics & Stem Cells Source Type: research
In this study we adopted an all-in-one method. Primers designed according to the two gRNA sequences and the tracRNA-U6 vector sequences were used to produce a gRNA1-tracRNA-U6-gRNA2 fragment. Then the proper fragment was ligated into the lentiCRISPRv2 vector and verified by sequencing. Lentiviral Packaging and Stable Cell Line Screening The constructed eukaryotic expression vector and gene knockdown vector were transfected into the 293T cells with the packaging plasmids psPAX2 and pMD2.G using Lipofectamine 2000 (Thermo Fisher, Massachusetts, USA). The lentivirus was harvested 48 h after transfection, and the lentivirus ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
Conclusions In this review, we analyzed mechanisms through which mitobolites, a distinct set of mitochondria-generated metabolites, can be released from mitochondria and then act as second messengers that contribute to cellular and organismal aging by regulating longevity-defining processes outside of mitochondria. Our analysis indicates that in eukaryotes across phyla, these second messengers of cellular aging exhibit the following common features: (1) they are produced in mitochondria in response to certain changes in the nutrient, stress, proliferation or age status of the cell; it remains unknown, however, what kind o...
Source: Frontiers in Physiology - Category: Physiology Source Type: research
Publication date: Available online 16 April 2019Source: Seminars in Cancer BiologyAuthor(s): Samanta Salvi, Massimiliano Bonafè, Sara BravacciniAbstractThe possibility that a receptor for androgen is expressed in Breast Cancer (BC) is fascinating given that the tumor is predominantly estrogen-dependent.The androgen receptor (AR) is emerging as a new marker and a potential new therapeutic target in the treatment of BC patients. The recent availability of selective AR inhibitors (e.g. bicalutamide, enzalutamide, apalutamide) approved for the treatment of prostate cancer has opened up the possibility to use them in BC ...
Source: Seminars in Cancer Biology - Category: Cancer & Oncology Source Type: research
Conclusions and Perspectives In this review, we have discussed important milestones from the early description of “Serum-sickness” as being due to antibodies directed against Neu5Gc epitopes all the way to the present-day therapeutic implications of these antibodies in cancer therapy. Some of these milestones have been represented in a concise timeline (Figure 6). While the “Xenosialitis” hypothesis is well-supported in the human-like mouse models, it has yet to be conclusively proven in humans. It remains to be seen if “Xenosialitis” plays a role in other uniquely-human diseases. FI...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Dan Hu1†, Meijin Zhang2†, Hejun Zhang1, Yan Xia1, Jinxiu Lin2, Xiongwei Zheng1, Feng Peng2* and Wenquan Niu3* 1Department of Pathology, Fujian Cancer Hospital &Fujian Medical University Cancer Hospital, Fuzhou, China 2Department of Cardiology, First Affiliated Hospital of Fujian Medical University, Fuzhou, China 3Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing, China Background and Objectives: Growing evidence indicates that metabolic syndrome confers a differential risk for the development and progression of many types of cancer, especially in the digestive tr...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Drugs & Pharmacology | Endocrine Therapy | Health | Legislation | National Institutes of Health (NIH) | Pediatrics | Politics | Prostate Cancer | Research | Study